E
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics
About Elstar Therapeutics
Marengo Therapeutics is a biotech startup that operates in the healthcare industry, specifically in the field of cancer treatment. The company's primary focus is on developing innovative therapies that harness the power of the body's own immune system to fight cancer. They have developed a unique therapeutic platform that selectively enhances certain subsets of a patient's T cells, transforming them into powerful cancer-fighting agents. This approach not only helps in combating the disease but also promotes long-term immunity, helping to keep cancer at bay.
The company's groundbreaking approach involves a novel method of T cell activation. The scientists at Marengo have discovered a new way to activate specific T cell subsets and combat tumors by directly targeting Variable β (Vβ) chain variants of the TCR. In simpler terms, they have found a way to "switch on" certain cells in the immune system that are particularly effective at fighting cancer.
Marengo's business model revolves around the development and commercialization of their first-in-class bispecific antibody library. This library allows for the selective activation and expansion of a wide range of different Vβ TCR variants, essentially providing a vast array of potential cancer-fighting cells ready to be activated when needed. The company generates revenue through the development, licensing, and sale of these innovative cancer therapies.
In summary, Marengo Therapeutics is a pioneering biotech startup that is revolutionizing cancer treatment by harnessing the power of the body's own immune system. Their innovative approach and unique therapeutic platform have the potential to make a significant impact in the fight against cancer.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2021 | $80M | $320M | Apple Tree Partners | ↗ |
| SERIES AOther financing | Jan 2018 | $39M | $156M | Apple Tree Partners | — |
Growth signals
Latest recorded traffic for Elstar Therapeutics is 4.9K monthly website visits, up 75% over the last three months. Elstar Therapeutics's team grew 2.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Elstar Therapeutics in the Cambridge ecosystem
The Elstar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Apple Tree Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elstar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elstar Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









